We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current SLRN market cap is 316.03M. The company's latest EPS is USD -3.8040 and P/E is -0.83.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -42.7M | -94.42M | -105.11M | -82.77M | -93.03M |
Net Income | -26.04M | -83.94M | -95.21M | -34.97M | -85.67M |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 |
Operating Income | -69.18M | -422.06M |
Net Income | -64.77M | -381.64M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Total Assets | 835.13M | 800.49M | 742.69M | 697.48M | 651.74M |
Total Liabilities | 34.06M | 68.11M | 86.35M | 53.42M | 83.52M |
Total Equity | 801.07M | 732.38M | 656.34M | 644.07M | 568.22M |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Assets | 319.92M | 742.69M |
Total Liabilities | 26.19M | 86.35M |
Total Equity | -102.86M | 656.34M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Operating | -56.95M | -96.07M | -169.71M | -57.3M | -103.57M |
Investing | -220.33M | -355.14M | -447.74M | 100.9M | 11.71M |
Financing | 566.34M | 565.84M | 568.44M | 2.81M | 2.52M |
Year End 31 December 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Operating | -61.52M | -169.71M |
Investing | -47.87M | -447.74M |
Financing | 274.26M | 568.44M |
Market Cap | 316.03M |
Price to Earnings Ratio | -0.83 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 1.45 |
Price to Book Ratio | 0.48 |
Dividend Yield | - |
Shares Outstanding | 100.33M |
Average Volume (1 week) | 876.92k |
Average Volume (1 Month) | 817.92k |
52 Week Change | -55.76% |
52 Week High | 8.885 |
52 Week Low | 3.105 |
Spread (Intraday) | 2.02 (40.08%) |
Company Name | ACELYRIN Inc |
Address |
1209 orange st wilmington, delaware 19801 |
Website | https://www.acelyrin.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions